Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303. (March 2022) - Zhou, Caicun; Huang, Dingzhi; Yu, Xinmin; Liu, Yunpeng; Fan, Yun; Shu, Yongqian; Ma, Zhiyong; Wang, Ziping; Cheng, Ying; Wang, Jie; Hu, Sheng; Liu, Zhihua; et al.